Mind + Muscle

technical minds + legal muscle

Bracket

dig deep

The Secret of Success

  • 07.02.14
  • Paul A. Calvo, Ph.D.
  • European Biopharmaceutical Review

In this article, Paul A. Calvo, Ph.D. discusses the growth of biosimilars that is leading many biopharmaceutical firms to seek second-generation patents, particularly for antibody production. "With respect to biosimilars, the reason for increased interest in keeping information secret is the sense that many originator companies will bypass filing for patent protection," said Dr. Calvo. The article discusses patent hurdles, prior user defense, trade secrets, business flexibility, and inter partes reviews.

To read the full article, please download the attached PDF.

Sort By Media Type

Sort By Media Type
  • AlertAlert
  • BriefsBriefs
  • Comments to USPTOComments to USPTO
  • Design Patent Case DigestDesign Patent Case Digest
  • MultimediaMultimedia
  • News & ArticlesNews & Articles
  • Press ReleasePress Release
  • VideoVideo
  • WebinarWebinar
X

Unsolicited e-mails and information sent to Sterne, Kessler, Goldstein & Fox P.L.L.C. will not be considered confidential or privileged, may be disclosed to others, may not receive a response, and do not create an attorney-client relationship with Sterne Kessler.  If you are not already a client of Sterne Kessler, do not include any confidential information in this message.